EUCTR2017-002954-35-SK进行中（未招募）1 期
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk - AMPLITUDE-O
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 5,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Type 2 Diabetes Mellitus with glycosylated hemoglobin (HbA1c) > 7%.
- •-Age 18 years or older with established cardiovascular disease or age 50 years (male), 55 years (female) or older with eGFR =25 and <60 mL/min and at least one cardiovascular risk factor.
- •-Female patients must agree to follow contraceptive guidance.
- •-Signed written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 3000
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2000
排除标准
- •-Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting.
- •-History of chronic pancreatitis or acute idiopathic pancreatitis or diagnosis of any type of acute pancreatitis within 3 months prior to screening.
- •-Personal or family history of medullary thyroid cancer (MTC)
- •-Hypertension (with a systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg).
- •-Hospitalization for hypertensive emergency within 3 months prior to randomization
- •-Planned coronary procedure or surgery after randomization.
- •-No documented ophthalmologic exam with fundoscopy within 6 months prior to screening
- •-Retinopathy or maculopathy with treatment, either recent (3 months prior to randomization) or planned during the study
- •-Treated with any glucagon-like peptide-1 (GLP-1) receptor agonist products (eg, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide) or in combination within 3 months prior to screening.
- •-Use of any DPP4 inhibitor within 3 months prior to screening
- •-Antihyperglycemic treatment has not been stable within 3 months prior to screening.
研究者
相似试验
进行中（未招募）
1 期
Evaluation of Dupilumab in Children with Uncontrolled Asthma (Liberty Asthma Voyage)MedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2016-001607-23-HUSanofi-Aventis Recherche & Développement785
进行中（未招募）
1 期
Effect of Efpeglenatide on Cardiovascular OutcomesType 2 diabetes mellitusMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-002954-35-FIsanofi-aventis recherche & développement5,000
进行中（未招募）
1 期
A Clinical Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s DiseaseEarly Alzheimer’s DiseaseMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2020-000116-30-SEJanssen-Cilag International NV420
进行中（未招募）
1 期
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskType 2 diabetes mellitusChronic kidney diseaseMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2017-002644-32-NOSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT16,154
进行中（未招募）
1 期
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-006165-11-PLJanssen-Cilag International NV350